BR112019023754A2 - anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. - Google Patents

anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. Download PDF

Info

Publication number
BR112019023754A2
BR112019023754A2 BR112019023754A BR112019023754A BR112019023754A2 BR 112019023754 A2 BR112019023754 A2 BR 112019023754A2 BR 112019023754 A BR112019023754 A BR 112019023754A BR 112019023754 A BR112019023754 A BR 112019023754A BR 112019023754 A2 BR112019023754 A2 BR 112019023754A2
Authority
BR
Brazil
Prior art keywords
sirpalpha
pharmaceutical composition
bind
antibodies
antibody
Prior art date
Application number
BR112019023754A
Other languages
English (en)
Inventor
Rouwendal Gerard
Franciscus Maria Verheijden Gijsbertus
Lottie Matlung Hanke
Franke Katarina
Jan Arends Roland
Kars Van Den Berg Timo
Original Assignee
Synthon Biopharmaceuticals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Biopharmaceuticals Bv filed Critical Synthon Biopharmaceuticals Bv
Publication of BR112019023754A2 publication Critical patent/BR112019023754A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção se refere a anticorpos contra sirpalpha que são adequados para uso em terapia anticâncer. a invenção se refere ainda ao uso dos anticorpos anti-sirpalpha no tratamento de tumores sólidos humanos e malignidades hematológicas, opcionalmente, em combinação com outras terapêuticas anticâncer. os anticorpos anti-sirpalpha descritos são mais específicos do que os anticorpos anti-sirpalpha conhecidos, enquanto mostram excelente afinidade por ambos, sirpalphal e sirpalphabit. em uma modalidade, os anticorpos anti-sirpalpha não se ligam ao sirpgamma. em uma segunda modalidade, os anticorpos anti-sirpalpha não se ligam ao sirpgamma e não se ligam ao sirpbetalvl. em uma terceira modalidade, os anticorpos anti-sirpalpha não se ligam ao sirpgamma e não se ligam ao sirpetalv2. em uma quarta modalidade, os anticorpos anti-sirpalpha não se ligam ao sirpbetalvl.
BR112019023754A 2017-05-16 2018-05-15 anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. BR112019023754A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17171285 2017-05-16
PCT/EP2018/062473 WO2018210793A2 (en) 2017-05-16 2018-05-15 ANTI-SIRPα ANTIBODIES

Publications (1)

Publication Number Publication Date
BR112019023754A2 true BR112019023754A2 (pt) 2020-06-09

Family

ID=58714966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023754A BR112019023754A2 (pt) 2017-05-16 2018-05-15 anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.

Country Status (14)

Country Link
US (2) US11274159B2 (pt)
EP (1) EP3625259B1 (pt)
JP (1) JP7171617B2 (pt)
KR (1) KR20200005659A (pt)
CN (1) CN110799536B (pt)
AR (1) AR111630A1 (pt)
AU (1) AU2018268304A1 (pt)
BR (1) BR112019023754A2 (pt)
CA (1) CA3063622A1 (pt)
CL (1) CL2019003266A1 (pt)
MX (1) MX2019013749A (pt)
RU (1) RU2771174C2 (pt)
TW (1) TWI710574B (pt)
WO (2) WO2018210795A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
JP7173971B2 (ja) 2016-12-09 2022-11-16 アレクトル エルエルシー 抗ＳＩＲＰ－α抗体及びその使用方法
KR20190140454A (ko) * 2017-04-13 2019-12-19 아두로 바이오테크 홀딩스, 유럽 비.브이. 항-sirp 알파 항체
WO2019183266A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
BR112020023844A2 (pt) 2018-05-25 2021-04-13 Alector Llc Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
CA3099176A1 (en) * 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
MX2021005761A (es) * 2018-11-15 2021-08-11 Byondis Bv Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
EP4349413A2 (en) 2019-10-18 2024-04-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
US20210154269A1 (en) 2019-11-27 2021-05-27 ALX Oncology Inc. Combination therapies for treating cancer
CN116621981A (zh) * 2019-12-24 2023-08-22 礼新医药科技(上海)有限公司 抗SIRPα单克隆抗体及其用途
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
JP2023528341A (ja) 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
JP2024501134A (ja) * 2020-11-30 2024-01-11 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗ＳＩＲＰα抗体またはその抗原結合断片および適用
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4337190A1 (en) 2021-05-13 2024-03-20 ALX Oncology Inc. Combination therapies for treating cancer
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
AU2022284373A1 (en) 2021-06-04 2024-01-04 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
CN116472351A (zh) * 2021-08-17 2023-07-21 杭州九源基因工程有限公司 靶向SIRPα的单克隆抗体及其用途
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2023235754A1 (en) 2022-06-01 2023-12-07 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU1701001A (en) 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
WO2006019447A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP3020730B1 (en) * 2011-01-19 2018-12-26 Cantargia AB Anti-il1rap antibodies and their use for treating solid tumours
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013150043A1 (en) * 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
US9845345B2 (en) * 2015-05-18 2017-12-19 Ab Initio Biotherapeutics, Inc. SIRP polypeptide compositions and methods of use
EP3365370A1 (en) * 2015-10-21 2018-08-29 OSE Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
AU2017248626B2 (en) * 2016-04-14 2024-05-09 Ose Immunotherapeutics New anti-SIRPa antibodies and their therapeutic applications
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效

Also Published As

Publication number Publication date
TW201906860A (zh) 2019-02-16
RU2019141289A3 (pt) 2021-09-17
US20220195063A1 (en) 2022-06-23
US11274159B2 (en) 2022-03-15
MX2019013749A (es) 2020-01-15
EP3625259A2 (en) 2020-03-25
US11718681B2 (en) 2023-08-08
KR20200005659A (ko) 2020-01-15
AU2018268304A1 (en) 2019-11-14
CA3063622A1 (en) 2018-11-22
EP3625259B1 (en) 2024-04-17
RU2019141289A (ru) 2021-06-16
WO2018210793A2 (en) 2018-11-22
RU2771174C2 (ru) 2022-04-28
WO2018210795A1 (en) 2018-11-22
JP7171617B2 (ja) 2022-11-15
TWI710574B (zh) 2020-11-21
CN110799536A (zh) 2020-02-14
JP2020520370A (ja) 2020-07-09
CN110799536B (zh) 2024-04-26
CL2019003266A1 (es) 2020-03-13
WO2018210793A3 (en) 2018-12-20
AR111630A1 (es) 2019-07-31
US20210070874A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
BR112019023754A2 (pt) anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12019500270A1 (en) Combination therapy for cancer
BR112019022972A2 (pt) Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
BR112018068363A2 (pt) fármaco terapêutico indutor de dano celular para uso em terapia de câncer
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
BR112017002080A2 (pt) ?anticorpo monoclonal ou fragmento de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para preparar o anticorpo monoclonal ou fragmento de ligação, in vivo ou in vitro e para prevenção e/ou tratamento e/ou terapia adjuvante e/ou diagnóstico de um tumor, conjugado, kit, uso de um anticorpo monoclonal ou fragmento de ligação, e, composição farmacêutica?
BR112018009064A8 (pt) anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
BR112017010324A2 (pt) método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
BR112019007267A2 (pt) anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
BR112015032690A2 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
BR112016027912A2 (pt) molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
BR112019005305A2 (pt) compostos espirocíclicos
BR112016013861A2 (pt) conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
AU2024202102A1 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
BR112018006817A2 (pt) método de tratamento do câncer
BR112018007318A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, e, métodos para tratar uma doença ou condição.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
BR112021009275A2 (pt) Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: SYNTHON BIOPHARMACEUTICALS B.V (NL)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870200073242, DE 12/06/2020, E NECESSARIO APRESENTAR PROCURACAO COM O NOME ATUAL DA EMPRESA, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: BYONDIS B.V. (NL)

B350 Update of information on the portal [chapter 15.35 patent gazette]